Celcuity Inc. (NASDAQ:CELC – Get Free Report) has received an average rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $29.17.
Several brokerages have issued reports on CELC. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Celcuity in a research note on Friday, November 15th. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Celcuity in a report on Friday, November 15th. Lifesci Capital initiated coverage on Celcuity in a report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price objective on the stock. Finally, Stifel Nicolaus increased their target price on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, October 7th.
Get Our Latest Report on Celcuity
Institutional Inflows and Outflows
Celcuity Trading Down 0.8 %
NASDAQ:CELC opened at $12.00 on Friday. Celcuity has a 12-month low of $11.51 and a 12-month high of $22.19. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The stock’s 50 day simple moving average is $14.14 and its 200-day simple moving average is $15.40. The firm has a market cap of $445.56 million, a P/E ratio of -4.60 and a beta of 0.74.
About Celcuity
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Further Reading
- Five stocks we like better than Celcuity
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Micron Stock Under $100: Seize the AI-Driven Upside
- Profitably Trade Stocks at 52-Week Highs
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.